Risk of Sequelae after *Chlamydia trachomatis* Genital Infection in Women

Catherine L. Haggerty, Sami L. Gottlieb, Brandie D. Taylor, Nicola Low, Fujiie Xu, and Roberta B. Ness

Department of Epidemiology, University of Pittsburgh, Pittsburgh, Pennsylvania; Division of STD Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia; The University of Texas School of Public Health, Houston; and Institute of Social and Preventive Medicine, University of Bern, Switzerland

*Chlamydia trachomatis* infection, the most common reportable disease in the United States, can lead to pelvic inflammatory disease (PID), infertility, ectopic pregnancy, and chronic pelvic pain. Although *C. trachomatis* is identified among many women who receive a diagnosis of PID, the incidence and timing of PID and long-term sequelae from an untreated chlamydial infection have not been fully determined. This article examines evidence reviewed as part of the Centers for Disease Control and Prevention Chlamydia Immunology and Control Expert Advisory Meeting; 24 reports were included. We found no prospective studies directly assessing risk of long-term reproductive sequelae, such as infertility, after untreated *C. trachomatis* infection. Several studies assessed PID diagnosis after untreated chlamydial infection, but rates varied widely, making it difficult to determine an overall estimate. In high-risk settings, 2%–5% of untreated women developed PID within the ∼2-week period between testing positive for *C. trachomatis* and returning for treatment. However, the rate of PID progression in the general, asymptomatic population followed up for longer periods appeared to be low. According to the largest studies, after symptomatic PID of any cause has occurred, up to 18% of women may develop infertility. In several studies, repeated chlamydial infection was associated with PID and other reproductive sequelae, although it was difficult to determine whether the risk per infection increased with each recurrent episode. The present review critically evaluates this body of literature and suggests future research directions. Specifically, prospective studies assessing rates of symptomatic PID, subclinical tubal damage, and long-term reproductive sequelae after *C. trachomatis* infection; better tools to measure PID and tubal damage; and studies on the natural history of repeated chlamydial infections are needed.

Genital infection with *Chlamydia trachomatis*, the most common reportable disease in the United States [1], can lead to serious sequelae among women, including pelvic inflammatory disease (PID), tubal factor infertility, ectopic pregnancy, and chronic pelvic pain [2–7]. Approximately 8% of US women and 15% of Swedish women have reported a PID diagnosis in their lifetimes [8–10]. PID is thought to occur as microorganisms ascend from the lower genital tract, infecting and causing inflammation of the uterus, fallopian tubes, and ovaries [11]. Although the microbial etiology of PID is not fully delineated, *C. trachomatis, Neisseria gonorrhoeae, Mycoplasma genitalium*, and microorganisms associated with bacterial vaginosis are frequently isolated from the lower and upper genital tracts of women with PID [12–17]. Although *C. trachomatis* is among the most frequent pathogens associated with symptomatic PID [15, 18, 19], isolated in the upper genital tract of up to a quarter of these patients [12, 18, 20], it has also been associated with a wide spectrum of upper genital tract pathology ranging from asymptomatic endometritis [21–25] to symptomatic, laparoscopically confirmed salpingitis [18]. This highlights the importance of this pathogen in the etiology of both acute PID and subclinical upper tract disease. The reproductive and gynecologic consequences of PID, including infertility [2, 7, 26, 27], ectopic pregnancy [2, 7, 26,
Because of the potential for *C. trachomatis* infection to cause serious sequelae, chlamydia screening and treatment programs have been implemented in many countries to shorten the duration of infection, prevent tubal damage among those infected, and reduce *C. trachomatis* transmission. However, recent surveillance data in several countries, including the United States, suggest that chlamydia rates have not been decreasing, despite ongoing control efforts [30, 31]. This has raised several fundamental questions about the natural history of *C. trachomatis* infection [32]. For example, if *C. trachomatis* infections were not detected and treated through a control program, what proportion would result in sequelae? This influences the overall potential benefit of the program and its cost-effectiveness. An even more important consideration may be the timing of tubal inflammation and damage relative to acquisition of infection. This timing affects the likelihood that infections can be detected and treated by a control program before development of symptomatic PID or development of tubal damage that could ultimately lead to infertility or ectopic pregnancy. Contributing to observed increases in chlamydia case rates is likely an increase in repeat infections, which are common in some populations [33]. Thus, another fundamental question is how harmful repeated *C. trachomatis* infections are in leading to sequelae. This review was developed to address these key questions, which were raised at the April 2008 Chlamydia Immunology and Control Expert Advisory Meeting sponsored by the Centers for Disease Control and Prevention (CDC). This article critically examines evidence addressing the risk and timing of female reproductive tract sequelae after untreated *C. trachomatis* infection and after repeated chlamydial infection. Gaps in knowledge are identified, and future research needs are proposed.

**METHODS**

A 3-member committee was composed to systematically identify the literature for review. A search of the literature from 1950 through 2008 was conducted with the Medline computerized database of the US National Library of Medicine. The term “*Chlamydia trachomatis*” was combined with “pelvic inflammatory disease,” “salpingitis,” “endometritis,” “infertility,” or “ectopic pregnancy.” A separate search was conducted as follows: “pelvic inflammatory disease,” “salpingitis,” or “endometritis” and “infertility” or “ectopic pregnancy.” This yielded a total of 3308 citations. Citations were then limited to human studies involving nonpregnant women, and postabortion and transcervical instrumentation studies were excluded. Additional articles were identified by cross-listing bibliographies of reviewed articles. The selected literature was examined for content, and 24 articles deemed to be most relevant to the key questions were selected for critical review. Six articles examined the prospective risk of PID after untreated chlamydial infection [34–39], and 12 examined risk of long-term reproductive sequelae after PID, including either PID of any cause [7, 15, 27–29, 40] or *C. trachomatis*-associated PID [2, 4, 20, 26, 41, 42]. Two articles prospectively explored the risk of PID after detected and treated chlamydial infection [43, 44], and 6 provided information on the risk of sequelae associated with repeated infection [4, 7, 19, 45–47]. These studies are discussed narratively in the text, and information on study design, population, methods, exposure and outcome measurement, results, strengths, and limitations were tabulated (Tables 1–5).

**RESULTS**

**What is the Risk of Sequelae over Time after an Untreated *C. trachomatis* Infection?**

The ultimate objective of chlamydia control programs is to prevent the most serious long-term reproductive consequences of *C. trachomatis* infection—mainly, infertility [48]. However, this outcome may not be recognized for several years after a chlamydial infection has caused tubal damage, because the affected woman may not have tried to become pregnant. In addition, there are ethical and technical limitations in following the natural course of infection, because an infection should be treated promptly once it is detected. Thus, although a number of case-control studies have demonstrated associations between serologic evidence of past chlamydial infection and either tubal factor infertility [5, 49–52] or ectopic pregnancy [3, 53, 54], there are no prospective studies directly evaluating risk of long-term reproductive tract morbidity after untreated *C. trachomatis* infection. PID can serve as a surrogate or intermediary outcome, because its temporal relationship to both chlamydial infection and long-term outcomes is more conducive to study and because it has substantial morbidity and costs [8, 11]. Several studies have attempted to assess the proportion of untreated *C. trachomatis* infections leading to PID [34–39], and another set of studies evaluated the proportion of PID cases leading to infertility and ectopic pregnancy [2, 4, 7, 15, 20, 26–29, 40–42]. Synthesizing these data can offer some insight into the risk of long-term sequelae after untreated chlamydial infection.

**PID after untreated chlamydial infection.** It is challenging to assess the true incidence of PID among women with untreated *C. trachomatis* infection. Despite this, several studies have described aspects of the natural history of untreated chlamydial infection (Table 1). In 3 investigations involving populations at high risk, occurrence of clinically diagnosed PID in women with untreated chlamydial infection was assessed during the ∼14-day interval between testing and treatment. PID occurrence in this interval ranged from 2% to 4.5% among
<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>No. of women with untreated C. trachomatis infection</th>
<th>Setting</th>
<th>Symptoms</th>
<th>Design</th>
<th>CT tests used</th>
<th>PID diagnosis</th>
<th>Duration of follow-up</th>
<th>Incidence of PID</th>
<th>Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stamm et al [39] (1984)</td>
<td>20</td>
<td>STD clinics in Seattle, WA, and Boston, MA (1980s)</td>
<td>Known or suspected uncomplicated Neisseria gonorrhoeae infection; C. trachomatis prevalence 26% in study population</td>
<td>Prospective cohort of C. trachomatis-positive women within RCT of N. gonorrhoeae treatment regimens</td>
<td>Culture</td>
<td>Clinical examination</td>
<td>7 weeks</td>
<td>30% (95% CI, 13%–53%; 6 of 20 women) in penicillin plus probenecid arm (ineffectively treated C. trachomatis); 2% (1 of 50) among those in other arms (treated more effectively for C. trachomatis with trimethoprim-sulfamethoxazole or tetracycline)</td>
<td>Small sample size; generalizability may be limited because of initial coinfection with N. gonorrhoeae; timing of C. trachomatis acquisition unknown</td>
</tr>
<tr>
<td>Rahm et al [38] (1986)</td>
<td>109</td>
<td>Adolescents seeking contraceptive at a counselling bureau in Sweden (1980s)</td>
<td>Healthy, asymptomatic, but C. trachomatis prevalence 15.6% in study cohort</td>
<td>Prospective natural history study</td>
<td>Culture</td>
<td>Hospitalized for salpingitis or seen in emergency department for lower abdominal pain/discharge</td>
<td>12 weeks</td>
<td>3.7% (95% CI, 1.2%–8.6%; 4 of 109 women)</td>
<td>Moderate length of follow-up is a strength; underestimation of PID possible as women not seeking medical care for abdominal pain would be excluded from the definition; timing of C. trachomatis acquisition unknown</td>
</tr>
<tr>
<td>Hook et al [36] (1994)</td>
<td>93</td>
<td>2 Baltimore STD clinics (1991); predominately young, black, low socioeconomic status</td>
<td>Primarily asymptomatic; excluded women with MPC, PID, or sex partners with STD; C. trachomatis test positivity 6.6%</td>
<td>Prospective evaluation of PID occurring between initial screening visit and return for treatment</td>
<td>Culture</td>
<td>Clinical examination</td>
<td>Median 14 days</td>
<td>3.2% (95% CI, 0.8%–8.5%; 3 of 93 women); cases presented 14, 23, and 68 days after initial positive test</td>
<td>Follow-up data available for 74% of C. trachomatis-positive women; relatively short length of follow-up; rate of PID in the C. trachomatis-negative group unknown; high-risk population; timing of C. trachomatis acquisition unknown</td>
</tr>
</tbody>
</table>
Almost all symptomatic (91\%) but not treated for C. trachomatis at initial visit; C. trachomatis test positivity at hospital 7.7\%.

Retrospective cohort study of PID after C. trachomatis testing

Culture and EIA

Clinical diagnosis documented in medical chart

4.5\% (95\% CI, 1.1\%–11.7\%; 3 of 67 women)

Moré et al [37] (2002)

30 Low-risk women undergoing screening as part of medical check-up before job engagement, Amsterdam (1995–1997)

Healthy, asymptomatic; C. trachomatis prevalence 4\%

Prospective natural history study

NAAT; urine specimens every 3 months tested at end of study

Self-reported doctor diagnosis, complaints of lower abdominal pain, or use of C. trachomatis-specific antibiotics

1 year 0\% (95\% CI, 0\%–9.5\%; 0 of 30 women)

Small sample size; ability to evaluate a longer duration of untreated C. trachomatis is a strength; limited by classification of PID by self-report; NAATs may detect infections with lower bacterial burden, perhaps less likely to progress to PID; timing of C. trachomatis acquisition unknown


115 Birmingham, Alabama, STD clinic (median age, 21 years)

Primarily asymptomatic; C. trachomatis prevalence not reported

Prospective evaluation of PID occurring between initial screening visit and return for treatment

Culture (70\%) or NAAT (30\%)

Clinical examination Median 13 days

2\% (95\% CI, 0.3\%–6.6\%; 2 of 115 women); 1 of the 2 women developing PID acquired a new N. gonorrhoeae infection during follow-up; cases presented 7 and 25 days after initial positive test result

Relatively short duration of follow-up; rate of PID in the C. trachomatis-negative group unknown; high-risk population; NAATs may detect infections with lower bacterial burden, perhaps less likely to progress to PID, timing of C. trachomatis acquisition unknown

NOTE. Data from the Prevention of Pelvic Infection (POPI) trial, an additional study of the risk of PID after untreated C. trachomatis infection, were published too late for inclusion in this review but are available elsewhere [70]. CI, confidence interval; EIA, enzyme immunoassay; MPC, mucopurulent cervicitis; NAAT, nucleic acid amplification test; RCT, randomized controlled trial; STD, sexually transmitted disease

a Number of women with untreated C. trachomatis infection who were evaluated for PID at follow-up.
<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Population</th>
<th>Setting</th>
<th>Study design</th>
<th>PID diagnosis</th>
<th>Outcomes</th>
<th>Period</th>
<th>Findings</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Westström et al [7] (1992)</td>
<td>1844 women with laparoscopically confirmed salpingitis and 657 control women with clinically suspected PID but normal laparoscopy findings; inpatients</td>
<td>University Hospital, Lund, Sweden (1960–1984)</td>
<td>Prospective cohort study</td>
<td>Laparoscopy</td>
<td>Infertility (failure to conceive despite regular unprotected intercourse for &gt;1 year); tubal factor infertility verified by HSG, laparoscopy, laparotomy, or combination</td>
<td>Case and control women followed up for 13,400 and 3958 woman-years, respectively</td>
<td>Failure to conceive among subgroup of women trying: 209 (16%) of 1309 case women, 12 (2.7%) of 451 control women; proportion with tubal factor infertility (excluding those with incomplete fertility evaluations): 141 (11.1%) of 1262 case women, 0 (0%) of 442 control women; severity of salpingitis on laparoscopy associated with infertility: mild (0.6% tubal factor infertility), severe (21.4% tubal factor infertility); ectopic pregnancy in first pregnancy: 9.1% of case women, 1.4% of control women (P &lt; .001)</td>
<td>Strengths: well done, landmark study with large sample size, laparoscopic confirmation of PID, and HSG identification of tubal factor infertility; control group</td>
<td>May not be generalizable to modern day microbiological and clinical setting; outcome data presented as proportions, so rate of complications over time not known</td>
</tr>
</tbody>
</table>

| Stacey et al [27] (1992) | 22 women treated for PID | STD clinic or Samaritan Hospital, London, England (1984–1987) | Prospective study | Laparoscopically confirmed salpingitis | Infertility and chronic pelvic pain evaluated by chart review, clinic examinations, and fertility questionnaires | 1–3 years after enrollment | S (33%) of 15 of women reported difficulty conceiving and 9 (56%) of 16 reported continued pelvic pain after 1 year | Lengthy follow-up and laparoscopic evaluation of PID | Small sample size and loss to follow-up; no control group |
| Buchan et al. [28] (1993) | 1200 women hospitalized with first diagnosis of PID and 10,507 control women discharged with other diagnoses | Oxford Record Linkage Study (1970–1985) | Retrospective cohort study | Discharge diagnosis and surgical confirmation (375 cases) | Subsequent hospital admissions for ectopic pregnancy, abdominal pain, endometriosis, hysterectomy, and recurrent PID | Followed up to 15 years | Abdominal pain admissions: 16.7% case women vs 1.7% control women (RR 9.8; 95% CI not presented); ectopic pregnancy: 1.9% case women vs 0.2% control women (RR 9.5; 95% CI not presented); hysterectomy: 18.2% case women vs 2.3% control women (RR 7.9; 95% CI not presented) | Large sample size | Women with secondary admission of PID excluded; may not be generalizable to modern setting; women who moved out of area covered by linkage system were missed |
| Lepine et al. [29] (1998) | 1288 hospitalized for salpingitis (same population as [7]) | Lund, Sweden (1960–1984) | Prospective cohort study | Laparoscopy | Live birth | 12 years follow-up | Cumulative live birth rates differed by severity of PID: mild salpingitis (90%), moderate salpingitis (82%), severe salpingitis (67%); compared with women with one case of mild PID, women with severe PID and subsequent diagnoses were more likely not to achieve a live birth (RR, 8.1; 95% CI 3.0–22.2) | Large sample size and laparoscopic confirmation of PID | May not be generalizable to modern microbiological and clinical setting |
| Ness et al. [15] (2002) | 831 women enrolled in a RCT of inpatient vs outpatient treatment of mild to moderate PID, recruited from ED, gynecology, STD clinics, and private practice; predominantly black, lower socioeconomic status; one-third reported prior diagnosis of PID | 13 US urban clinical sites, 1996–1999 (PEACH study) | RCT | Clinical examination | Interviews every 3–4 months for outcomes of infertility lack of pregnancy with sex for 12 months with no effective contraception), ectopic pregnancy, chronic pelvic pain (consistent self-reports of pain of at least 6 months duration), recurrent PID (self-report), pregnancy rate, time to pregnancy | Mean 35 months follow-up | No differences in outcomes by treatment arm; cumulative outcomes over ~3 years: infertility (18%), ectopic pregnancy (0.6%), chronic pelvic pain (29%), recurrent PID (14%); pregnancy achieved in 42%; mean time to pregnancy 21 months | Large sample size and lengthy follow-up with active assessment for outcomes; modern-day assessment of multiple outcomes after mild-moderate clinically suspected PID | PID diagnosis by clinical criteria alone and no outcomes among control group reported here (see Haggerty et al. [23, 41] in Table 4) |
Heinonen and Leinonen [40] (2003)  
39 women treated with doxycycline plus metronidazole for salpingitis  
Hospital of Tampere, Finland (1983–1988)  
Prospective cohort study  
Laparoscopy  

<table>
<thead>
<tr>
<th>Questionnaires and hospital chart review for pregnancy, recurrent infections, and infertility</th>
<th>Mean follow-up of 125 ± 44 months</th>
</tr>
</thead>
<tbody>
<tr>
<td>28 women (72%) tried to conceive during the follow-up period: 25 (89%) conceived and 11 (28%) avoided conception; no statistically significant difference (P = .06) in cumulative pregnancy rates between mild and severe salpingitis groups; mean time to pregnancy, 38 months; many of these women may have been considered infertile at some point using a standard infertility definition (lack of conception after 12 months of unprotected intercourse), suggests relationship between PID and subfertility</td>
<td>Laparoscopic confirmation of PID and lengthy follow-up for sequelae</td>
</tr>
</tbody>
</table>

Small sample size, self-report of pregnancy, and use of a treatment regimen no longer recommended

**NOTE.** CI, confidence interval; ED, emergency department; EIA, enzyme immunoassay; HSG, hysterosalpingogram; NAAT, nucleic acid amplification test; RCT, randomized controlled trial; RR, relative risk; STD, sexually transmitted disease.
Table 3. Studies Assessing the Risk of Reproductive and Gynecologic Sequelae after Chlamydia trachomatis–Associated Pelvic Inflammatory Disease (PID)

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Population</th>
<th>Setting</th>
<th>Study design</th>
<th>PID diagnosis</th>
<th>Outcomes</th>
<th>Period</th>
<th>Findings</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brunham et al [2] (1988)</td>
<td>71 women hospitalized for PID</td>
<td>Winnipeg, Canada (1983–1987)</td>
<td>RCT of doxycycline plus clindamycin vs doxycycline plus metronidazole (14 days)</td>
<td>Clinical examination; salpingitis confirmed by laparoscopy in 50 women</td>
<td>Interviews of women about intercourse without contraception and pregnancies; HSG performed on a few women</td>
<td>Follow-up: 5–7 months</td>
<td>0 of 10 women with N. gonorrhoeae PID had an adverse reproductive outcome, compared with 7 of 13 women with nongonococcal PID (P &lt; .007), but only 3 of 7 infertile women had evidence of past or present CT (antibody or culture)</td>
<td>Laparoscopic confirmation of PID</td>
<td>Small sample size, small subgroup analyses, loss to follow-up, and short follow-up time for reproductive outcomes</td>
</tr>
<tr>
<td>Safrin et al [26] (1992)</td>
<td>51 of 140 women originally admitted for inpatient PID</td>
<td>San Francisco General Hospital (1985)</td>
<td>Retrospective cohort study</td>
<td>Hospital discharge diagnosis of PID, salpingitis, or tuboovarian abscess</td>
<td>Involuntary infertility (failure of conception after &gt;1 year of unprotected intercourse); ectopic pregnancy; chronic pelvic pain (pelvic pain for &gt;6 months); recurrent PID diagnosis</td>
<td>Telephone interview to assess long-term sequelae 3-4 years later</td>
<td>27% of 118 women C. trachomatis culture positive; among 51 women in retrospective cohort: involuntary infertility (40%), chronic pelvic pain (24%), recurrent PID (43%); ectopic pregnancy (2.4%); C. trachomatis did not significantly predict infertility in the entire cohort (data not reported); however, positive C. trachomatis culture result associated with involuntary infertility in women in whom index PID episode was the first (RR, 2.5; 95% CI, 1.0–6.2); C. trachomatis not associated with infertility among women with recurrent PID at admission (P = .5)</td>
<td>Lengthy follow-up</td>
<td>64% of patients could not be located and interviewed; small sample size; greater number of interviewed women had a tuboovarian abscess during index admission</td>
</tr>
<tr>
<td>Study</td>
<td>Sample Size and Population</td>
<td>Study Design</td>
<td>Inclusion Criteria</td>
<td>Follow-up</td>
<td>Main Findings</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------------------------</td>
<td>--------------</td>
<td>--------------------</td>
<td>-----------</td>
<td>---------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hillis et al [42] (1993)</td>
<td>443 women hospitalized for PID; included only those with cultures positive for C. trachomatis and/or Neisseria gonorrhoeae at time of PID (same population as [7])</td>
<td>Nested case-control study in prospective cohort of sequelae after PID</td>
<td>Clinically suspected by examination (not limited to those with laparoscopic confirmation)</td>
<td>4–14 years of follow-up</td>
<td>Overall, C. trachomatis monoinfection not more likely to be associated with impaired fertility than N. gonorrhoeae monoinfection or dual infection (OR, 0.9; 95% CI, 0.5–1.7); C. trachomatis associated with delayed care for PID (OR, 2.1; 95% CI, 1.0–4.1); delayed care associated with impaired fertility (OR, 2.6; 95% CI, 1.2–5.9); early treatment among women with C. trachomatis PID was strongly protective: 18 (18%) of 101 of those delaying care had impaired fertility compared to 0 (0%) of 13 of those seeking care promptly (P &lt; 0.05); this effect was much less pronounced for N. gonorrhoeae infection</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haggerty et al [20] (2003)</td>
<td>614 women with clinically suspected PID recruited from ED, gynecology, STD clinics, and private practice (same population as [15])</td>
<td>Prospective cohort study</td>
<td>Clinically suspected by examination (all patients in cohort); endometrial biopsy with histology, C. trachomatis NAAT, and N. gonorrhoeae culture; endometritis (&gt;5 neutrophils or &gt;2 plasma cells)</td>
<td>2–5 years</td>
<td>Endometritis and/or endometrial infection with C. trachomatis or N. gonorrhoeae not associated with increased sequelae compared with clinically suspected PID without endometritis or endometrial infection; reduced pregnancy (OR, 0.8; 95% CI, 0.6–1.2); elevated infertility (OR, 1.0; 95% CI, 0.6–1.6); chronic pelvic pain (OR, 0.6; 95% CI, 0.4–0.9); recurrent PID (OR, 0.6; 95% CI, 0.4–0.9); 11 (19%) of 64 of those with endometrial C. trachomatis had infertility vs 81 (16.8%) of 523 of those without endometrial C. trachomatis (not significantly different); no differences for any other outcomes according to endometrial C. trachomatis result during baseline PID episode</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Large sample size; done within well-executed cohort with long follow-up; results may not be generalizable to modern microbiologic and clinical setting; all women in the study had clinically suspected PID with C. trachomatis or N. gonorrhoeae infection; thus, relationship between C. trachomatis and impaired fertility biased to the null; however, suggests C. trachomatis PID no more or less likely to cause sequelae than N. gonorrhoeae PID.
<table>
<thead>
<tr>
<th>Study</th>
<th>Participants</th>
<th>Study Design</th>
<th>Endometrial Histology</th>
<th>Follow-up</th>
<th>Findings</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haggerty et al [41] (2005)</td>
<td>780 women with clinically suspected PID, recruited from ED, gynecology, STD clinics, and private practice (same population as [15])</td>
<td>Prospective cohort study</td>
<td>Endometrial histology</td>
<td>Chronic pelvic pain, defined as pain reported at ≥2 consecutive interviews conducted every 3–4 months</td>
<td>2–5 years</td>
<td>Endometritis or evidence of endometrial Neisseria gonorrhoeae or C. trachomatis infection was negatively associated with chronic pelvic pain (adjusted OR, 0.69; 95% CI, 0.44–1.10)</td>
<td>Large sample size and lengthy follow-up; histologic confirmation of PID; modern-day assessment with active follow-up for outcomes of PID</td>
</tr>
<tr>
<td>Ness et al [4] (2008)</td>
<td>443 women with clinically suspected mild to moderate PID (same population as [15])</td>
<td>Prospective study</td>
<td>Clinical examination; serologic assessment: ELISA for antibodies to C. trachomatis EB and to Chsp60 at baseline and in final 2 years of follow-up</td>
<td>Times to pregnancy and recurrent PID</td>
<td>Mean of 84 months</td>
<td>Women whose anti-C. trachomatis EB antibodies in the final year of follow-up were in the highest tertile had: lower pregnancy rates (aHR, 0.47; 95% CI, 0.3–0.8), higher PID recurrence (aHR, 2.48; 95% CI, 1.0–6.3); baseline anti-C. trachomatis EB antibodies and antibodies to Chsp60 at either time point were not significantly associated with reproductive morbidity</td>
<td>Large sample size and serologic assessment of C. trachomatis, measuring cumulative exposure over a given time frame</td>
</tr>
</tbody>
</table>

**NOTE.** aHR, adjusted hazard ratio; Chsp60, Chlamydia heat shock protein 60; CI, confidence interval; EB, elementary bodies; ED, emergency department; ELISA, enzyme-linked immunosorbent serologic assay; HR, hazard ratio; HSG, hysterosalpingogram; NAAT, nucleic acid amplification test; RCT, randomized controlled trial; RR, relative risk; STD, sexually transmitted disease.
### Table 4. Studies Assessing the Risk of Sequelae after at Least 1 Detected and Treated *Chlamydia trachomatis* Infection

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>No. of women with treated C. trachomatis infection</th>
<th>Setting</th>
<th>Population</th>
<th>Methods</th>
<th>Duration of follow-up</th>
<th>Incidence of PID</th>
<th>Validity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ness et al [44]  (2006)</td>
<td>122</td>
<td>1170 women enrolled from family planning, university health and gynecology clinics, and STD units at 5 clinical US sites (1999–2001); predominately African-American women aged 13–36 years</td>
<td>Not specifically seeking care for an STD, but at elevated risk for chlamydial cervicitis, based on a scoring system; baseline C. trachomatis prevalence 10.2%</td>
<td>Prospective cohort study to assess risk factors for PID</td>
<td>Clinical examinations and C. trachomatis and <em>Neisseria</em> gonorrhoeae testing every 6–12 months; C. trachomatis test: NAAT</td>
<td>Median 3 years</td>
<td>Cumulative incidence of PID according to baseline C. trachomatis and <em>N. gonorrhoeae</em> results: C. trachomatis positive (18.8%), <em>N. gonorrhoeae</em> positive (18.8%), no infection (7.0%), overall (8.6%)</td>
</tr>
<tr>
<td>Low et al [43]   (2006)</td>
<td>2965</td>
<td>Laboratory, hospital, and population registry data from all 43,715 women aged 15–24 years in Uppsala, Sweden (1985–1989); followed up for outcomes through 1999</td>
<td>Retrospective population-based cohort study linking C. trachomatis test history and results with hospital codes</td>
<td>Culture (for most) and NAAT</td>
<td>Hospital diagnosis codes</td>
<td>10–14 years</td>
<td>Cumulative incidence of PID by age 35 years: C. trachomatis positive (5.6%), C. trachomatis negative (4.0%), not tested (2.9%), overall (3.9%); C. trachomatis positive vs. C. trachomatis negative: HR for PID, 1.5 (95% CI, 1.2–1.8), adjusted HR, 1.3 (95% CI, 1.0–1.6) controlling for demographic and socioeconomic factors</td>
</tr>
</tbody>
</table>

**NOTE.**  
CI, confidence interval; ED, emergency department; EIA, enzyme immunoassay; HR, hazard ratio; NAAT, nucleic acid amplification test; PID, pelvic inflammatory disease; STD, sexually transmitted disease.  
*a* Number of women with detected and treated C. trachomatis infection at baseline who were evaluated for PID at follow-up.
### Table 5. Studies Assessing the Risk of Sequelae after Repeat Chlamydia trachomatis Infections

<table>
<thead>
<tr>
<th>Reference (year)</th>
<th>Population</th>
<th>Setting</th>
<th>Study design</th>
<th>C. trachomatis and PID diagnosis</th>
<th>Outcomes</th>
<th>Time interval</th>
<th>Findings</th>
<th>Strengths</th>
<th>Limitations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weström et al [7] (1992)</td>
<td>1844 women with laparoscopically confirmed salpingitis and 657 control women with clinically suspected PID but normal laparoscopy findings; inpatients</td>
<td>University Hospital, Lund, Sweden (1960–1984) (see Table 2)</td>
<td>Prospective cohort study</td>
<td>Laparoscopy</td>
<td>Infertility (failure to conceive despite regular unprotected intercourse for &gt;1 year), tubal factor infertility verified by HSG, laparoscopy, laparotomy, or combination</td>
<td>Case and control women followed up for 13,400 and 3958 woman-years, respectively</td>
<td>Main results presented in Table 2; results related to repeat episodes of salpingitis; each case roughly doubled the risk of tubal factor infertility: after 1 episode salpingitis (8%), after 2 episodes salpingitis (19.5%), after 3 episodes salpingitis (40%)</td>
<td>Large sample size, laparoscopic confirmation of PID, and HSG identification of tubal factor infertility; control group</td>
<td>May not be generalizable to modern microbiological and clinical setting; assessed sequelae after repeat PID episodes, not after repeat C. trachomatis infection</td>
</tr>
<tr>
<td>Hillis et al [46] (1997)</td>
<td>11,000 women aged 10–44 years with at least one C. trachomatis infection; 644 with ≥3 C. trachomatis infections, 2044 with 2 C. trachomatis infections, 8312 in random sample of women with 1 infection; C. trachomatis period prevalence 11% (family planning), 13% (STD clinics)</td>
<td>Family planning and STD clinics, Wisconsin (1985–1992)</td>
<td>Retrospective cohort study of number of C. trachomatis infections and subsequent PID or ectopic pregnancy hospitalizations, using linked registry data</td>
<td>PID and ectopic pregnancy hospital discharge codes in statewide registry</td>
<td>7-year follow-up period</td>
<td>After adjustment, elevated risks of PID and ectopic pregnancy among women with more infections; PID: 1 infection (referent), 2 infections (OR, 4.0; 95% CI, 1.6–9.9), ≥3 infections (OR, 6.4; 95% CI, 2.2–18.4); ectopic pregnancy: 1 pregnancy (referent), 2 pregnancies (OR, 2.1; 95% CI, 1.3–3.4), ≥3 pregnancies (OR, 4.5; 95% CI, 1.8–5.3)</td>
<td>Population-based, cohort design</td>
<td>Unable to distinguish persistent vs new reinfection; no information on potential confounders; hospital discharge data may not be accurate and no outpatient data; clinicians may be more likely to diagnose PID in women with history of repeated C. trachomatis infections</td>
<td></td>
</tr>
<tr>
<td>Study</td>
<td>Participants</td>
<td>Design</td>
<td>Endpoints</td>
<td>Findings</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>--------------</td>
<td>--------</td>
<td>-----------</td>
<td>----------</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kimani et al [47] (1996)</td>
<td>302 urban female sex workers; mean age, 31 years; 54% HIV positive; 146 women had at least 1 C. trachomatis infection; 98 had uncomplicated cervical infection only; 23 had C. trachomatis PID, 25 had C. trachomatis and Neisseria gonorrhoeae infection</td>
<td>Prospective cohort study evaluating risk factors for C. trachomatis PID vs uncomplicated C. trachomatis infection</td>
<td>Presence of new pelvic and adnexal tenderness on exam</td>
<td>Followed up for mean of 17.6 months</td>
<td>Independent risk factors for C. trachomatis PID included repeated C. trachomatis infection (adjusted OR, 1.8; 95% CI, 1.3–2.4; <em>P</em> = .004); women with C. trachomatis PID had more episodes of C. trachomatis infections (<em>P</em> = .001), but risk of PID per C. trachomatis infection among those with 1 infection (0.07 ± 0.26) was similar to that among women with repeated infections (0.13 ± 0.23; <em>P</em> = .15)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ness et al [19] (2004)</td>
<td>684 women enrolled in RCT of inpatient vs outpatient treatment of mild to moderate PID; recruited from ED, gynecology, STD clinics, and private practice (same population as [15])</td>
<td>Prospective study</td>
<td>Clinical examination</td>
<td>Patients interviewed every 3–4 months for outcomes of infertility (lack of pregnancy within 12 months among those reporting no effective contraception), chronic pelvic pain consistent self-reports of pain of at least 6 months duration, recurrent PID (self-report)</td>
<td>Mean 35 months follow-up</td>
<td>Consistent condom use associated with lower risk for infertility (RR, 0.4; 95% CI, 0.2–0.9), chronic pelvic pain (RR, 0.7; 95% CI, 0.5–1.2), recurrent PID (RR, 0.5; 95% CI, 0.3–0.9)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Special clinic in Nairobi, Kenya (1991) Prospective cohort study evaluating risk factors for C. trachomatis PID vs uncomplicated C. trachomatis infection EIA Presence of new pelvic and adnexal tenderness on exam Followed up for mean of 17.6 months Independent risk factors for C. trachomatis PID included repeated C. trachomatis infection (adjusted OR, 1.8; 95% CI, 1.3–2.4; *P* = .004); women with C. trachomatis PID had more episodes of C. trachomatis infections (*P* = .001), but risk of PID per C. trachomatis infection among those with 1 infection (0.07 ± 0.26) was similar to that among women with repeated infections (0.13 ± 0.23; *P* = .15) |

Prospective, well-done study showing multiple C. trachomatis infections associated with developing C. trachomatis PID rather than just C. trachomatis cervicitis Small sample size in the C. trachomatis PID group, power limited to assess per infection risk; generalizability limited given high-risk Kenyan sex worker cohort

Prospective study Clinical examination Patients interviewed every 3–4 months for outcomes of infertility (lack of pregnancy within 12 months among those reporting no effective contraception), chronic pelvic pain consistent self-reports of pain of at least 6 months duration, recurrent PID (self-report) Mean 35 months follow-up Consistent condom use associated with lower risk for infertility (RR, 0.4; 95% CI, 0.2–0.9), chronic pelvic pain (RR, 0.7; 95% CI, 0.5–1.2), recurrent PID (RR, 0.5; 95% CI, 0.3–0.9) Large sample size and lengthy follow-up; provides indirect evidence for association between repeat C. trachomatis and sequelae, as protective effect of condom use may be mediated by reduced exposure to C. trachomatis Reliance on self-reported condom use may underestimate association
<table>
<thead>
<tr>
<th>Study (Year)</th>
<th>Population</th>
<th>Methods</th>
<th>Findings</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bakken et al [45] (2007)</td>
<td>20,762 women born during 1970–1984 tested for <em>C. trachomatis</em>; 72,405 <em>C. trachomatis</em> tests done before first pregnancy; <em>C. trachomatis</em> period prevalence 18%</td>
<td>Retrospective cohort study on number of <em>C. trachomatis</em> infections and subsequent ectopic pregnancy using linked registry data~50% NAATs from 1 laboratory</td>
<td>Inpatient and outpatient ectopic pregnancy codes from county registry</td>
<td>Rate of ectopic pregnancy among those with pregnancies according to number of <em>C. trachomatis</em> infections: 0 infections (0.29 cases/PY; referent), 1 infection (0.58 cases/PY; aHR, 1.8 [95% CI, 1.1–3.0]), &gt;2 infections (1.39 cases/PY; aHR, 3.4 [95% CI, 1.5–8.0])</td>
</tr>
<tr>
<td>Ness et al [4] (2008)</td>
<td>443 women with clinically suspected mild to moderate PID (same population as [15])</td>
<td>Prospective study PID: clinical examination; serologic assessment: ELISA for antibodies to <em>C. trachomatis</em> EB and to Chsp60 at baseline and within final 2 years of follow-up</td>
<td>Times to pregnancy and recurrent PID</td>
<td>Women whose anti–<em>C. trachomatis</em> EB antibodies in the final year of follow-up were in the highest tertile had: lower pregnancy rates (aHR, 0.47; 95% CI, 0.3–0.8); higher PID recurrence (aHR, 2.48; 95% CI, 1.0–6.3); baseline anti–<em>C. trachomatis</em> EB antibodies and antibodies to Chsp60 at either time point were not significantly associated with reproductive morbidity</td>
</tr>
</tbody>
</table>

**NOTE.** aHR, adjusted hazard ratio; Chsp60, *Chlamydia* heat shock protein 60; CI, confidence interval; EB, elementary bodies; ED, emergency department; EIA, enzyme immunoassay; ELISA, enzyme-linked immunosorbent serologic assay; HR, hazard ratio; HSG, hysterosalpingogram; NAAT, nucleic acid amplification test; OR, odds ratio; PID, pelvic inflammatory disease; PY, person-years; RCT, randomized controlled trial; RR, relative risk; STD, sexually transmitted disease.
women returning for a follow-up visit [34–36]. In a study in 2 Baltimore sexually transmitted diseases (STD) clinics, 3 (3%) of 93 women who tested positive for *C. trachomatis* by culture developed PID within a median of 2 weeks between testing and treatment [36]. Similarly, in a prospective STD clinic study involving 129 adults who tested positive for *C. trachomatis* by culture and nucleic acid amplification tests (NAATs), 2 women (2%) received a diagnosis of PID at a treatment visit that occurred a median of 13 days later [35]. Both of these women had ongoing chlamydial infection, and one had acquired a new gonococcal infection [35]. In a retrospective chart review study, Bachmann et al [34] also investigated the occurrence of PID during the period between testing and treatment in 67 mostly symptomatic women who tested positive for *C. trachomatis* in an emergency department or other high-risk clinical setting and reported that 3 (4.5%) of 67 women who did not receive therapy at the time of initial evaluation received a diagnosis of PID when they returned for treatment.

If the mean rate observed in this 2-week period (∼3%) is assumed to be constant and to apply to all women with chlamydia, it would be expected that close to 18% of women would develop PID in 12 weeks, and >50% would develop PID in 1 year. However, 2 studies with longer follow-up periods did not report such high rates of PID (Table 1). The first, conducted in Sweden before the need to treat chlamydia was universally accepted, comprised 109 asymptomatic adolescent girls with untreated, culture-proven *C. trachomatis* infection, and 4 (3.7%) reported being hospitalized for salpingitis or seen in the emergency department for lower abdominal pain and vaginal discharge in the 3-month observation period [38]. In a more recent long-term follow-up study involving 30 healthy adult women who screened positive for *C. trachomatis* by NAAT, no women developed symptoms of chlamydial infection, none received *C. trachomatis*–specific antibiotic treatments, and none received a diagnosis of PID from her general practitioner or gynecologist within 1 year [37].

The highest estimate of PID after untreated chlamydial infection comes from a randomized trial in which 20 women coinfected with *C. trachomatis* and *N. gonorrhoeae* received adequate therapy for gonococcal but not chlamydial infection and were followed up for up to 7 weeks [39]. Six women (30%) received a diagnosis of PID from clinicians who were masked to the patients’ chlamydial culture results.

**Infertility and ectopic pregnancy after PID.** Several studies have shown increased risks of reproductive and gynecologic sequelae after PID of any cause (Table 2) [7, 15, 27–29, 40]. Most notably, a landmark prospective study of 2501 Swedish women that was conducted by Weström et al [7] from the 1960s through the 1980s found that 16% of women with laparoscopically confirmed salpingitis developed infertility, compared with 2.7% of control women with clinically suspected PID who did not have salpingitis determined by laparoscopic examination. Infertility was defined by inability to conceive after 1 year of attempting to become pregnant. Tubal factor infertility was confirmed in 11.1% of cases and in none of the control women. In addition, among women with salpingitis, 9.1% of first pregnancies were ectopic pregnancies, compared with 1.4% of first pregnancies among control women. The severity of PID on laparoscopic examination affected long-term outcomes. Overall, 26% of women with clinically suspected PID had normal-appearing tubes on laparoscopy; none of these women developed proven tubal factor infertility. Among women with a mild episode of salpingitis, only 0.6% developed tubal factor infertility, but 21% of those with a single episode of severe salpingitis had tubal factor infertility in ensuing years [7].

As part of a randomized controlled trial of treatment regimens for PID (the PID Evaluation and Clinical Health [PEACH] study), Ness et al [15] observed 831 women with mild to moderate clinically suspected PID for adverse outcomes during 1996–1999. Over a mean of 35 months of follow-up, 18% of the women reported infertility, 0.6% had an ectopic pregnancy, and 29% had some degree of chronic pelvic pain, with no differences by treatment arm. Among the 42% who became pregnant, the mean time to pregnancy was 21 months [15]. Laparoscopic verification of PID diagnoses, as done in the study by Weström et al [7], was not feasible in the PEACH study; however, endometrial biopsy was performed for a subset of 614 women [20, 41]. Rates of pregnancy, infertility, and chronic pelvic pain were not significantly different between women with and those without evidence of histologic endometritis [20, 41].

Some studies have also assessed the risk of infertility after PID that is specifically associated with *C. trachomatis* infection (Table 3) [2, 4, 20, 26, 41, 42]. In a retrospective cohort study involving 51 women hospitalized for PID in the 1980s, among women suffering their first episode of PID, those who were culture positive for *C. trachomatis* were more likely to experience involuntary infertility than were those who tested negative (relative risk, 2.5; 95% confidence interval [CI], 1.0–6.2) [26]. Furthermore, in a study involving women hospitalized during 1983–1987 for clinically suspected PID, 0 of 10 women with gonococcal PID experienced an adverse reproductive outcome, compared with 7 of 13 women with nongonococcal infection [2]. However, in a more recent study involving 614 women with clinically suspected PID, women with endometrial *C. trachomatis* infection had rates of subsequent infertility that were similar to those among women who did not have *C. trachomatis* detected in the endometrium (19% vs 16.8%) [20, 41]. In this study, endometritis and/or endometrial infection with *C. trachomatis* or *N. gonorrhoeae* was not associated with reduced pregnancy, elevated infertility, or increased chronic pel-
The reasons for this are unclear. Antichlamydial and gonococcal PID treatment might have reduced the degree of damage preferentially in women with these infections (compared with other causes of clinically suspected PID), and endometritis does not always correlate with salpingitis [55–57]. In addition, women in all groups of this high-risk cohort may have had prior or subsequent C. trachomatis infection that resulted in tubal damage before or after the baseline PID episode, biasing results to the null. Indeed, a separate serologic investigation in this cohort revealed an association between C. trachomatis elementary body antibodies measured during the final year of follow-up and lower pregnancy rates [4].

The symptoms of PID may be less severe with C. trachomatis infection than with N. gonorrhoeae infection [58], which, in turn, may cause women to delay care for PID. In a nested case-control study in the cohort observed by Weström et al [7], among 76 case women who experienced infertility or ectopic pregnancy and 337 control women with a subsequent intrauterine pregnancy after PID, C. trachomatis was not associated with impaired fertility overall, compared with other causes of PID (odds ratio [OR], 0.9; 95% CI, 0.5–1.7) [42]. Although C. trachomatis infection was associated with delayed care (OR, 2.1; 95% CI, 1.0–4.1), which, in turn, was strongly associated with impaired fertility (adjusted OR, 2.8; 95% CI, 1.3–6.1), prompt treatment of chlamydia-associated PID dramatically lowered the risk of sequelae much more so than did prompt treatment of gonococcal infection [42].

**Summary.** We found no prospective studies directly assessing risk of infertility after untreated C. trachomatis infection, and precise rates of progression are unknown. However, some data are available on risk of PID after untreated chlamydial infections and risk of infertility and other long-term outcomes after PID. The rate of PID after untreated C. trachomatis genital infection is challenging to determine accurately, because estimates vary widely across studies. In STD clinic or other high-risk populations in which untreated, detected chlamydial infections and risk of infertility and other long-term outcomes after PID. The rate of PID after untreated C. trachomatis infection was followed up for ~2 weeks, rates of short-term PID diagnosis ranged from 2% to 4.5% [34–36]. If these rates were extrapolated to longer periods, we would expect a greater proportion of patients to develop PID. However, in a population of asymptomatic, untreated C. trachomatis–positive adolescent girls seeking birth control in Sweden, PID occurred in 3.7% over 12 weeks [38]. In the lowest-risk population evaluated thus far, Mørre et al [37] observed no PID developing in 30 healthy adult women followed up for 1 year. All of these studies were relatively small and had limitations that could affect the accuracy of risk estimates. Nonetheless, differences in these results may be explained by several possible factors. First, PID rates may not be constant over time for several reasons. A disproportionate amount of PID might occur early in the course of chlamydial infection, when care-seeking in STD clinics or emergency departments is more likely because of recent high-risk behavior or symptoms. Host factors may contribute, with susceptible individuals developing tubal pathology early. Higher organism load may also play a role. In addition, immune responses developing over time could limit progression to the upper genital tract even when the infection is not resolved at the level of the cervix. Second, symptomatic infection prompting care-seeking may result in higher rates of PID than asymptomatic infection (eg, because of differences in host response). Third, there may be a lower threshold for PID diagnosis in high-risk settings or with a known untreated infection. Finally, PID rates may be higher in populations considered to be at high risk of sexually transmitted infections, because they may be more likely to have coinfections or bacterial vaginosis, have a history of PID, or experience recurrent infection [44]. Another factor that may influence differences among rates is the use of highly sensitive NAATs in some studies that may detect infections with a lower C. trachomatis burden and, perhaps, a lower likelihood for progression. The highest rates of PID were seen in the small (n = 20) but widely cited study by Stamm et al [39]. Coinfection with N. gonorrhoeae and a greater likelihood for recurrent chlamydial infection in this particularly high-risk population may explain the higher observed rate of sequelae.

After symptomatic PID has occurred, even with treatment, it is associated with significant reproductive and gynecologic morbidity, including infertility, ectopic pregnancy, and chronic pelvic pain [7, 15, 27–29, 40]. In the largest study of its kind, from the 1960s through the 1980s in Sweden, Weström et al [7] found that 16% of women with laparoscopically verified salpingitis developed infertility in the ensuing years, compared with 2.7% of control women with clinically suspected PID but no laparoscopic evidence of salpingitis. Ness et al [15] found that 18% of women developed infertility after clinically diagnosed PID during the 1990s in the United States, and the rate did not differ by presence or absence of histologic endometritis in a subsequent analysis by Haggerty et al [20]. In the study by Weström et al [7], severity of PID, as judged by laparoscopic examination, was associated with infertility, suggesting that tubal damage sustained at the time of acute PID may lead to sequelae [7, 29]. Among women with clinically suspected PID, none of those with normal-appearing tubes developed tubal factor infertility, whereas 21.4% of women with an episode of severe salpingitis did [7]. Although PID of any cause is strongly linked to sequelae [2, 4, 20, 26, 41, 42], data from the largest studies suggest that chlamydia PID is no more or less likely to lead to sequelae than other causes of PID [20, 41, 42].

When using PID as an intermediary outcome to estimate risk of long-term reproductive sequelae resulting from untreated C. trachomatis infection, it is important to understand the extent to which chlamydial infection may lead to these
sequelae outside the pathway involving symptomatic PID. Most women with tubal factor infertility and ectopic pregnancy have no history of diagnosed PID, including women in case-control studies showing strong associations between these outcomes and serologic evidence of past chlamydial infection [3, 5, 49]. However, in one study, further questioning of infertile women with no history of diagnosed PID revealed that 60% of those with tubal infertility reported health care visits for abdominal pain, compared with only 19% of those without tubal disease [59]. Nonetheless, it is known that chlamydial infection can cause asymptomatic or mildly symptomatic upper tract infection and inflammation [23, 25]. In addition, pathologic damage in fallopian tube biopsy specimens from women with tubal infertility is similar whether or not there is a history of overt PID [60]. Subclinical tubal infection and inflammation likely lead to some degree of infertility and other complications, but the full extent to which this occurs remains unclear.

**Research needs and future directions.** Quantifying the risks of PID, infertility, and ectopic pregnancy after untreated *C. trachomatis* infection would provide vital data for chlamydia control programs and for clinicians to share with patients on infection would provide vital data for chlamydia

In addition, laparoscopic examination has been found to be a sensitive marker of upper genital tract infection in a study involving 121 women meeting the CDC's minimal criteria for PID [67]. More work is needed to verify the diagnostic accuracy of these newer measures and additional inflammatory markers, such as interferon and other cytokines.

Next, to fully understand the natural history and sequelae of untreated chlamydial infection, we need additional prospective studies assessing rates of both clinically suspected PID and asymptomatic tubal inflammation after *C. trachomatis* infection in diverse populations encompassing the full spectrum of symptomatology and risk of sexually transmitted infection. Additional information on the 12-month incidence of PID after untreated *C. trachomatis* infection among asymptomatic college-aged women was recently collected as part of a randomized trial of chlamydia screening in the United Kingdom that was conducted before such screening was nationally recommended there [68, 69]. Although final results of the study were published too late for inclusion in this review, the natural history analysis revealed that 9.5% of 74 women with untreated chlamydial infection developed PID in 12 months [70]. Studying the timing of PID occurrence is also critical. The picture emerging from the studies listed in Table 1 suggests higher short-term rates of PID, with risk of PID decreasing after the first few weeks, and low rates within a year after asymptomatic infection. Understanding the timing of PID development is critical in optimizing the frequency and structure of chlamydial screening and other control strategies. Natural history studies are limited by the fact that it would be unethical to withhold treatment for diagnosed...
chlamydial infection, and it is unclear how long a woman has already had infection at the time it is detected through testing. Nonetheless, creative strategies to develop prospective studies of chlamydia natural history are vital. Innovative use of stored genital specimens from existing or ongoing prospective studies of other infections (eg, human papillomavirus vaccine trials and human immunodeficiency virus prevention trials) in which specimens are collected beyond those used to diagnose and treat chlamydial infection as part of standard medical practice might also provide opportunities for better understanding of chlamydia natural history. Any study of C. trachomatis natural history would have to be carefully designed to ensure protection of human subjects. Finally, because of the challenges facing accurate diagnosis of PID and the occurrence of asymptomatic chlamydial upper tract involvement, as well as the difficulties in obtaining better natural history data, primary and secondary prevention strategies for C. trachomatis infection and its sequelae should be a focus of future studies, as discussed by Gottlieb et al in this supplement [71].

A primary necessity for research on sequelae after PID is identification of better, more proximal markers of tubal damage that are predictive of long-term sequelae. This would not only allow the outcomes of chlamydial infection to be more accurately classified but would also make prospective research on chlamydia and long-term outcomes more feasible. The landmark study by Weström et al [7] provided excellent data on risk of sequelae among women who were hospitalized with PID, compared with a control group of women with abdominal pain who did not have laparoscopically verified PID. However, these data were obtained in Sweden 20–40 years ago in a potentially much different microbiological and clinical milieu (eg, higher prevalence of N. gonorrhoeae and older PID treatment regimens). The PEACH study provided modern-day estimates of adverse outcomes after mild to moderate PID in the United States and stratified participants according to endometrial biopsy results but did not include a control group of women without clinically suspected PID [15]. Additional studies evaluating reproductive and gynecologic morbidity among women with PID, compared with an appropriate control group, in a modern-day setting would be valuable. In addition, prospective studies evaluating the risk of reproductive sequelae after subclinical upper genital tract infection and inflammation are needed. Preliminary data from a prospective study showed that 17% of 58 women with subclinical endometritis at a baseline visit had evidence of fallopian tube damage demonstrated by hysterosalpingogram 3 months later, whereas only 8% of 362 women without endometritis had such evidence [72]. Final results from this study have not yet been published. Finally, current evidence suggests that the vast majority of women infected with C. trachomatis do not develop PID, and not all women with chlamydial PID become infertile. Host factors and immunologic predictors explaining differences in morbidity risk should be explored in future studies, as discussed by Darville et al in this supplement [73]. Differences in morbidity after C. trachomatis infection may also be explained by simultaneous infection with other pathogens, such as N. gonorrhoeae [15] and M. genitalium [74], and the impact of such coinfection should be explored in future studies of PID and its sequelae.

Is the Risk of Sequelae Increased during a Repeat Chlamydial Infection?

PID after ≥1 detected and treated chlamydial infection. A prospective assessment of PID after detected and treated C. trachomatis infection comes from a study of 1170 women from 5 US sites; all of the women were at high risk of chlamydia based on their demographic risk scores (Table 4) [44]. The women were tested for C. trachomatis and N. gonorrhoeae at baseline and were retested at follow-up visits every 6–12 months for a median of 3 years. Of these women, 122 tested positive for C. trachomatis at baseline and received antibiotic therapy. Twenty-three C. trachomatis–positive women (18.8%) received a diagnosis of PID (primarily mild to moderate) during follow-up. This rate of PID was substantially higher than that among women who did not have gonococcal or chlamydial cervicitis at baseline (7.0%). The etiology of subsequent PID episodes was unknown. The incidence of severe PID from any cause, stratified by C. trachomatis test history, was also assessed in a retrospective cohort study involving 43,715 Swedish women followed up from 1985 through 1999 [43]. Low et al [43] found that, by 15 years of follow-up, 6% of women had tested positive for C. trachomatis (and were assumed to have been treated), 4% of those who were screened and tested negative, and 3% of those never screened were subsequently treated for PID. Although some outpatient data were captured, most of the registry data were from inpatient records and, therefore, primarily measured the overall rate of severe PID. Women who tested positive for C. trachomatis were 50% more likely to be subsequently treated for PID than those who tested negative (hazard ratio [HR], 1.5; 95% confidence interval [CI], 1.2–1.8), although this relationship was attenuated when adjusted for demographic and socioeconomic factors (HR, 1.3; 95% CI, 1.0–1.6) [43].

Repeat infections with C. trachomatis are common [33, 75, 76] and may contribute to the higher incidence of PID among women at high risk [39, 44], compared with women in the general population [37]. Similarly, the higher risk of repeat chlamydial infection among women with ≥1 detected infection may help explain the higher rates of PID associated with longer follow-up of these women [43, 44].

PID after repeat chlamydial infection. The association between repeat infection and PID sequelae was assessed by a retrospective cohort study involving 11,000 women and girls
aged 10–44 years who tested positive for *C. trachomatis* in Wisconsin during 1985–1992 (Table 5) [46]. Women who tested positive twice were 4 times as likely (OR, 4.0; 95% CI, 1.6–9.9) and women who tested positive ≥3 times were >6 times as likely (OR, 6.4; 95% CI, 2.2–18.4) to receive a diagnosis of PID [46]. It is difficult to determine the true impact of repeat chlamydial infection on PID from this study, however, because clinicians may be more likely to diagnose PID in women with a history of repeated chlamydial infection. Similarly, a prospective cohort study involving 302 urban female sex workers in Nairobi, Kenya, reported a significant relationship between repeated *C. trachomatis* isolation and the cumulative risk of chlamydial PID over ∼18 months (adjusted OR, 1.8; 95% CI, 1.3–2.4) [47]. However, the risk of PID with each individual chlamydial infection appeared to be similar among those with one infection and repeated infections [47], although the power to detect a difference may have been limited. Thus, this study suggests that, although cumulative risk increases, the risk of PID per chlamydial infection may not be any greater with each recurrent episode. Although these studies were unable to distinguish between persistent and new repeat infection, they suggest that the risk of PID increases in parallel with the number of detected *C. trachomatis* infections.

Further demonstration of the relationship between recurrent chlamydial infection and risk of PID was evident in a prospective study involving 443 women with clinically suspected mild to moderate PID who were followed up for a mean of 84 months with repeated chlamydial serologic testing [4]. Although baseline antibodies to *C. trachomatis* elementary bodies were not associated with reproductive morbidity, rates of PID recurrence were higher among women whose anti-chlamydial antibodies were in the highest tertile during the final year of follow-up (adjusted OR, 2.5; 95% CI, 1.0–6.3). Later serologic testing, reflecting both baseline and subsequent chlamydial infections, was associated with PID recurrence, suggesting that additional exposures to *C. trachomatis* may increase the risk of subsequent PID [4]. Supporting this was the finding that consistent condom use in the same population was associated with a marked decrease in the incidence of recurrent PID [19].

**Long-term reproductive sequelae after repeat chlamydial infection.** In the same way that repeated chlamydial infection may increase the risk of PID, recurrent infection with *C. trachomatis* may also increase the risks of infertility and ectopic pregnancy. There is good evidence to suggest that recurrent PID increases sequelae risk, as first evidenced in the landmark Scandinavian cohort study involving 1844 women with laparoscopically confirmed salpingitis that was conducted by Westrom et al [7]. In this study, each episode of salpingitis roughly doubled the risk of tubal factor infertility (8% after 1 episode, 20% after 2 episodes, and 40% after 3 episodes) [7]. Similarly, the studies by Ness et al [4, 19], in which higher titers of anti-chlamydial antibodies at follow-up and less consistent condom use were linked with recurrent PID, also showed that these factors were associated with longer times to pregnancy. These findings suggest that additional exposures to *C. trachomatis* after an episode of PID can lead to an increased risk of long-term complications.

In the retrospective cohort study assessing diagnosed chlamydia and sequelae risk that was conducted by Hillis et al [46], women who were identified as *C. trachomatis* positive 2 times in Wisconsin county databases from 1985 through 1992 were twice as likely (OR, 2.1; 95% CI, 1.3–3.4) and those with ≥3 diagnosed infections were >4 times as likely (OR, 4.5; 95% CI, 1.8–5.3) to be hospitalized with an ectopic pregnancy. Another registry study involving 20,762 Norwegian women using the health care system from 1990 through 2003 reported a similar dose-response relationship between detected *C. trachomatis* infection and ectopic pregnancy [45]. Compared with women who tested negative for *C. trachomatis*, women with a history of a diagnosed chlamydial infection had almost a 2-fold increased risk of ectopic pregnancy (adjusted HR, 1.8; 95% CI, 1.1–3.0) and those with ≥2 diagnosed chlamydial infections had a 3-fold increased risk of ectopic pregnancy (adjusted HR, 3.0; 95% CI, 1.6–5.6) [45].

**Summary.** Long-term follow-up studies of the period after treated chlamydial infection show that women with ≥1 detected *C. trachomatis* infection have higher rates of PID in the ensuing years than do women without a detected infection, with PID rates near 20% over 3 years in a high-risk population [44]. Although a detected chlamydial infection may simply be a marker for high-risk sexual behavior and exposure to other sexually transmitted infections, one possible explanation for these findings is an increased risk of PID related to repeated *C. trachomatis* infections, which are common [75, 76].

Several studies have shown that the cumulative risk of PID [4, 46, 47] and long-term reproductive sequelae [4, 45, 46] increases with repeated chlamydial infections. However, it remains unclear from these epidemiologic studies whether the risk of sequelae from a given chlamydial infection is higher with each additional repeat infection. Furthermore, methodological problems make it difficult to sort out how much of the association between recurrent chlamydia and PID is attributable to biologically plausible mechanisms and how much is attributable to diagnostic ascertainment bias. Certainly, physicians’ knowledge about prior positive chlamydial results may influence their differential diagnosis of lower abdominal pain. Because of the asymptomatic nature of chlamydial infection, it is also difficult to determine how many chlamydial infections a woman has actually had, if she did not seek medical care. Furthermore, it is difficult to determine whether a first diag-
nosed infection is truly primary and how many past infections have occurred when there is evidence of past infection. In all of these studies, infections were detected and therefore treated; however, perhaps the most enhanced pathologic memory immune response may occur after an initial infection that has resolved on its own. Lastly, the inability to distinguish between persistent and repeat infection limits interpretation.

**Research needs and future directions.** Studies on the natural history of repeated chlamydial infections are needed. Such studies should determine how the risk of PID in a given period after a repeat infection compares with the risk of PID in an equivalent period after an initial infection. In addition, because it is difficult to determine whether a woman’s first diagnosed chlamydial infection is truly primary, natural history studies that conduct frequent *C. trachomatis* screenings and PID evaluations among a group of young, seronegative women are desirable. To conduct these natural history studies, a better understanding of chlamydia-associated antibodies would be valuable, in terms of the proportion of infections that result in seroconversion, the time course of seroconversion, duration of seroreactivity, and titers with initial and repeat infection. Furthermore, better markers of repeat infection and immunologic and host factors that predict worse tubal damage with repeat infection should also be explored [73]. Because of the high rates of PID from any cause in the years after a detected chlamydial infection in some populations [44], we also need studies of prevention strategies focused on women who have already received a diagnosis of at least one chlamydial infection.

Recently, Ness et al [19] reported that consistent condom use was associated with a 30%–60% reduction in recurrent PID in a subgroup of 684 sexually active women followed up after an initial episode of PID. However, additional studies are needed to confirm these data and to determine optimal prevention strategies after diagnosed chlamydial infection in addition to those after PID.

**CONCLUSION**

Although the evidence linking *C. trachomatis* with tubal pathology is strong, there remains a great deal of uncertainty about the progression rates of both PID and reproductive sequelae among women acquiring *C. trachomatis* infection. Furthermore, the ability to link a specific chlamydial infection with later reproductive and gynecologic morbidity is limited. Prospective studies assessing the rates of symptomatic PID, asymptomatic tubal damage, and reproductive sequelae after *C. trachomatis* infection; better tools to measure PID and tubal damage; and studies on the natural history of repeated chlamydial infections are needed to better understand the long-term risks of chlamydial infection.

**References**


71. Gottlieb SL, Berman SM, Low N. Screening and treatment to prevent sequelae in women with Chlamydia trachomatis genital infection; how much do we know? J Infect Dis 2010;201(Suppl 2):S156–S167 (in this supplement).